According to filings with the U.S. Securities and Exchange Commission, R3 Vascular is raising up to $72,499,781.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Christopher Owens played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About R3 Vascular
R3 Vascular is a privately-held Medical Device company that has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds (BVS) with a sirolimus coating for the treatment of peripheral artery disease (PAD) below the knee. PAD is the narrowing or blockage of the vessels that carry blood from the heart to the legs or lower extremities; it is primarily caused by the buildup of fatty plaque in the arteries, which is called atherosclerosis. PAD can happen in any blood vessel, but it is more common in the legs than the arms. It affects 200 million people globally. Approximately 6.5 million people at the age of 40 and older in the United States have PAD. These numbers continue to rise given the increasing burden of risk factors and an aging population. If a patient has PAD, they are at risk for developing coronary artery disease and cerebrovascular disease, which could lead to a heart attack or stroke as well. The R3 Vascular BVS platform combines the best of both worlds of BTK therapy, designed to deliver the stent-like support of a scaffold, along with the anti-inflammatory result of sirolimus, but disappearing over time as the vessel heals. R3 Vascular is headquartered in Mountain View, Calif., USA, with additional operations in Munich, Germany.

To learn more about R3 Vascular, visit http://www.r3vascular.com/
R3 Vascular Linkedin Page: https://www.linkedin.com/company/r3-vascular-inc/

Contact:
Christopher Owens, President and Chief Executive Officer
610-585-6867

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.